Studies on lactulose formulations for colon-specific drug delivery.
A novel, colon-targeted delivery system (CODES), which uses lactulose, was investigated in this study. Lactulose is not absorbed in the upper GI tract, but degraded to organic acids by enterobacteria in the lower gastrointestinal tract, especially the colon. A CODES consists of three components: a core containing lactulose and the drug, an inner acid-soluble material layer, and an outer layer of an enterosoluble material. When a CODES containing a pigment was introduced into the rat cecum directly after shaking in JP 2nd fluid for 3 h, pigment release was observed 1 h after introduction. A CODES containing 5-aminosalicylic acid (5-ASA) was orally administered to fasting and fed dogs to evaluate its pharmacokinetic profiles. 5-ASA was first detected in plasma after 3 h, which is the reported colon arrival time for indigestible solids, after dosing to fasting dogs. The T(max) in fed dogs was delayed by 9 h when compared to fasting dogs. This corresponds to the gastric emptying time. However, the C(max) and AUC under fed conditions were almost as same as those under fasting conditions. The results of this study show that lactulose can act as a trigger for drug release in the colon, utilizing the action of enterobacteria.
Katsuma
Masataka
M
DDS Research, Novel Pharmaceutical Laboratories, Yamanouchi Pharmaceutical Co Ltd, 180 Ozumi, Yaizu, Shizuoka 425-0072, Japan. katsuma@yamanouchi.co.jp
Watanabe
Shunsuke
S
Kawai
Hitoshi
H
Takemura
Shigeo
S
Masuda
Yoshinori
Y
Fukui
Muneo
M
D000818:Animals; D002626:Chemistry, Pharmaceutical; D003106:Colon / Q000187:drug effects* / Q000378:metabolism; D004285:Dogs; D016503:Drug Delivery Systems / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D007792:Lactulose / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013607:Tablets
D013607:Tablets; D007792:Lactulose